Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.82 |
| ▸ | PGK1 | P00558 | 1/20 | 0.78 |
| ▸ | PGK2 | P07205 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | NT5E | P21589 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8820659 | 1.00 | ADORA3 (0.82) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL9080619 | 0.91 | ADORA3 (0.82) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL9080624 | 0.91 | ADORA3 (0.82) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL14853634 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL5879766 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL14928752 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL18464461 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL6758941 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL4803033 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL27578766 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023152709-A1 | RNA POLYMERASE INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-17 | — | — | WO | claimed |
| WO-2023152709-A1 | RNA POLYMERASE INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-17 | — | — | WO | disclosed |
| US-7049303-B2 | Inhibition of viruses | MEDICAL RESEARCH COUNCIL (GB) | 2006-05-23 | — | — | US | disclosed |
| US-20050043268-A1 | Inhibition of viruses | MEDICAL RESEARCH COUNCIL (GB) | 2005-02-24 | — | — | US | disclosed |
| WO-1997033591-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| US-5589467-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1996-12-31 | — | — | US | disclosed |
| US-5430027-A | 2-chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias | NOVO NORDISK A/S (DK) | 1995-07-04 | — | — | US | disclosed |
| EP-0607367-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993023417-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043268-A1 | Inhibition of viruses | RNASE1, HNRNPA1, RNASEH1 | ADORA3 399/4885ADORA1 237/4885PGK1 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.